Natural Born Killers: NK Cells in Cancer Therapy
Round 1
Reviewer 1 Report
Optional: An updated on the Wels study with Her-2 new NK-92 cells is mentioned in: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02683/full
Also suggest to quote an ASH abstract from 2018 describing a t-haNK for CD19 engineered to express the CCR7 homing receptor (abstract #116890)
Author Response
July 20, 2020
Re: cancers-875047
Natural Born Killers: NK Cells in Cancer Therapy
Specific Points:
NOTE: Changes in BLUE
REVIEWER 1:
- An updated on the Wels study with Her-2 new NK-92 cells is mentioned in: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02683/full
Response:
We thank the reviewer for this suggestion. The article mentioned is a review (CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy). We have now referenced the trials discussed in the review (manuscript references 99-102).
- Also suggest to quote an ASH abstract from 2018 describing a t-haNK for CD19 engineered to express the CCR7 homing receptor (abstract #116890) all in-vitro
Response:
We understand. The noytes ASH abstract describes the in-vitro utilization of a t-haNK for CD19 engineered to express the CCR7 homing receptor. To focus our review, we limited our comments to clinical data at the expense of in-vitro only data. If the reviewer insists, we can add it.
Reviewer 2 Report
Well written review article on NK cells in cancer therapy that includes several pertinent recent studies. Concise and very easy to read. Figures are well-done, clear and self-explanatory.
Some minor comments that should be addressed:
- please include trade names of the drugs in lines 39 and 40.
- include the word "cell" after NK in lines 83, 86 and 88.
- Should include a brief discussion on the cytotoxic molecules referred to in line 128.
- the authors refer to several CAR-NK therapy in lines 324-329. Are these using NK-92 cell line or primary human NK cels. A sentence should be added to clarify this.
- what does t-ha-NK refer to in line 356 ? please clarify.
- spell out TME in line 332.
- please include appropriate reference for the statement in lines 465-467.
Author Response
July 20, 2020
Re: cancers-875047
Natural Born Killers: NK Cells in Cancer Therapy
Specific Points:
NOTE: Changes in BLUE
REVIEWER 2:
- Please include trade names of the drugs in lines 39 and 40.
Response:
We appreciate this comment. However, as United States Federal Employees, we are forbidden form listing trade names, as this may imply an endorsement of a particulat drug by the government. We are strongly encouraged to use the generic names for drugs.
- include the word "cell" after NK in lines 83, 86 and 88.
Response:
As suggested, this has now been added.
- Should include a brief discussion on the cytotoxic molecules referred to in line 128.
Response:
Thank you for this comment. As suggested, this has now been added.
- the authors refer to several CAR-NK therapy in lines 324-329. Are these using NK-92 cell line or primary human NK cells. A sentence should be added to clarify this.
Response:
As recommended, we have now clarified this in Table 1.
- what does t-ha-NK refer to in line 356 ? please clarify.
Response:
Thanks. This has now been clarified.
- spell out TME in line 332.
Response:
Thank you. As suggested, this has now been clarified.
- please include appropriate reference for the statement in lines 465-467.
Response:
This has now been completed.